ACC Latin America Conference 2016
MEXICO CITY
OCTOBER 7 – 8, 2016
For more information, visit ACC.org/LatinAmerica2016

UNIQUE EDUCATIONAL EXPERIENCE IN YOUR REGION
ACC Latin America Conference 2016

MEXICO CITY
OCTOBER 7 - 8, 2016

For more information, visit
ACC.org/LatinAmerica2016
Case Presentation

- Female, 32 years
- No medical record
- 7 days before hospitalization, began with fever, malaise, sore throat, and chest pain that increases with respiration, she start antibiotics
• 4 days before, presents syncope.
• Went to another hospital and they found hypotension, signs of low cardiac output, ECG with QS complex V1-V5, cardiac enzymes positive.
• They started norepinephrine and dobutamine.
• Decide to transfer the patient to our institute.
• We received the patient with BP 81/63 (67), HR 132, RR 32, T 35.5, decreased consciousness, jugular venous distension, pulmonary rales, 3rd sound.
Electrocardiogram
TAPSE: 12mm
S: 6cm
TRJ: 2.2m
<table>
<thead>
<tr>
<th>Date</th>
<th>Condition</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>25.01.16</td>
<td>Fever, malaise, sore throat, chest pain</td>
<td></td>
</tr>
<tr>
<td>28.01.16</td>
<td>Syncope. Hypotension, low perfusion</td>
<td>Start NE Dobutamine</td>
</tr>
<tr>
<td>01.02.16</td>
<td>GC 2 IC 1.1</td>
<td></td>
</tr>
<tr>
<td>02.02.16</td>
<td>HR 90</td>
<td>BP 74/44 PWP 8 CO 4.7 CI 2.8 SVR 1241 CVP 7</td>
</tr>
<tr>
<td>03.02.16</td>
<td>HR 120</td>
<td>BP 96/55 PWP 10 CO 3.6 CI 2.5 SVR 1576 d CVP 6</td>
</tr>
<tr>
<td>04.02.16</td>
<td>HR 98</td>
<td>BP 120/54 PWP 10 CO 7.2 CI 4.3 SVR 633 PVC 16</td>
</tr>
<tr>
<td>05.02.16</td>
<td>8:20</td>
<td>BP 130/60 PWP 19 CO 7.7 CI 4.5 SVR 644 CVP 17</td>
</tr>
<tr>
<td>06.02.16</td>
<td>- Withdraw mechanical ventilation</td>
<td></td>
</tr>
</tbody>
</table>
Questions?
Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies*
Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials

European Heart Journal (2009) 30, 2102–2108
**Figure 3** Meta-analysis showing the relative risk of crude 30-day mortality with use of percutaneous left ventricular assist devices. Random effects model was used for meta-analysis. Relative risks with 95% confidence intervals are presented on the right of the figure. IABP, intra-aortic balloon pump; LVAD, left ventricular assist device.
Thank you